Menu
Home
About Us
About Noxopharm
Board of Directors
Management Team
Our Science
About Veyonda
Publications
Pipeline & Clinical Programs
Investors
Share Price
ASX Announcements
Nox Insights
Media
NoxoBlog
Newsletters
Presentations & Interviews
Annual Reports
Financial Reports
Quarterly Reports
Analyst Reports
Corporate Governance
Company Constitution
Privacy Policy
Investor FAQs
Investors Glossary
Upcoming Events
Contact Us
Contact Us
Working at Noxopharm
Email Alerts
NOX:
Market Cap:
Price Delay ~20min
Investors
Home
>
Investors
>
Analyst Reports
Share Price
ASX Announcements
Nox Insights
Media
NoxoBlog
Newsletters
Presentations & Interviews
Annual Reports
Financial Reports
Quarterly Reports
Analyst Reports
Corporate Governance
Company Constitution
Privacy Policy
Investor FAQs
Investors Glossary
Upcoming Events
Analyst Reports
5-Sep-2018
EverBlu Capital Research Report: A Closer Look at Nyrada - a Noxopharm subsidiary company.
12-Jul-2018
Noxopharm Research Report prepared by EverBlu Capital Research July 2018
27-Jul-2017
NOX Research Report prepared by APP Securities
25-May-2017
Independent Investment Research Report May 2017
16-Nov-2016
Independent Investment Research Report November 2016
19-Sep-2016
APP Securities Company Research Report September 2016
